Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Swedberg, K; Borer, JS; Pitt, B; Pocock, S; Rouleau, J (2016)
Publisher: Massachusetts Medical Society
Languages: English
Types: Article
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • tion in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14.
    • 11. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
    • 12. Maggioni AP, Greene SJ, Fonarow GC, et al. Effect of aliskiren on post-discharge outcomes among diabetic and nondiabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013;34:3117-27.
    • 13. McMurray JJV, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. DOI: 10.1056/NEJMoa1514859
    • 14. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59.
    • 15. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.
    • 16. Tougas G, Aftring RP. Novartis reply to the ATMOSPHERE data monitoring committee. N Engl J Med. DOI: 10.1056/ NEJMc1603515
    • 17. Salmonson T, Janssen H, Sudhop T, Stahl E. Regulatory reply to the ATMOSPHERE data monitoring committee. N Engl J Med. DOI: 10.1056/NEJMc1603514 DOI: 10.1056/NEJMsb1601674 Copyright © 2016 Massachusetts Medical Society.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article